These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 9933848)

  • 1. Prevention and management of platelet transfusion refractoriness.
    Novotny VM
    Vox Sang; 1999; 76(1):1-13. PubMed ID: 9933848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions.
    Abraham AS; Chacko MP; Fouzia NA; Srivastava A; Daniel D
    Transfus Med; 2018 Oct; 28(5):392-397. PubMed ID: 29460307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical aspects of platelet transfusion therapy.
    Murphy MF
    Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():34-8. PubMed ID: 7841778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.
    Couvidou A; Rojas-Jiménez G; Dupuis A; Maître B
    Front Immunol; 2023; 14():1125367. PubMed ID: 36845153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China.
    Xia WJ; Ye X; Tian LW; Xu XZ; Chen YK; Luo GP; Bei CH; Deng J; Santoso S; Fu YS
    Transfus Med; 2010 Aug; 20(4):269-74. PubMed ID: 20136782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
    Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
    Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR; Guo L; Vassallo R
    Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory factors that affect the post-transfusion platelet increment.
    Fabris F; Soini B; Sartori R; Randi ML; Luzzatto G; Girolami A
    Transfus Sci; 2000 Aug; 23(1):63-8. PubMed ID: 10925055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
    Stanworth SJ; Navarrete C; Estcourt L; Marsh J
    Br J Haematol; 2015 Nov; 171(3):297-305. PubMed ID: 26194869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation.
    Marktel S; Napolitano S; Zino E; Cappelli B; Chiesa R; Poli F; Crocchiolo R; Ronchi P; Rossini S; Ciceri F; Roncarolo MG; Fleischhauer K
    Pediatr Transplant; 2010 May; 14(3):393-401. PubMed ID: 20070557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM].
    Dettori I; Ladaique P
    Transfus Clin Biol; 2014 Nov; 21(4-5):207-9. PubMed ID: 25267204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility.
    Valsami S; Dimitroulis D; Gialeraki A; Chimonidou M; Politou M
    Asian J Transfus Sci; 2015; 9(2):117-23. PubMed ID: 26420927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of platelet transfusions.
    Murphy MF; Waters AH
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.